Startseite Kongressberichte 2019 15th International Conference on Malignant Lymphoma (ICML) T-CELL LYMPHOMAS

T-CELL LYMPHOMAS

P. Ghione, New York, NY (USA), et al. 

RISK OF BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA (BIA-ALCL) IN A COHORT OF 3546 WOMEN PROSPECTIVELY FOLLOWED AFTER RECEIVING TEXTURED BREAST IMPLANTS.

Authors Conclusion from the abstract: This study, evaluating the risk of women with textured breast implants from a prospective database with long‐term follow‐up, demonstrated that the incidence rate of BIA‐ALCL may be higher than previously reported. These results can help inform implant choice for women undergoing breast reconstruction.

 

M. Lopez-Parra, Salamanca (Spain), et al.

AUTOLOGOUS STEM CELL TRANSPLANTATION AS PART OF FIRST-LINE THERAPY IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA: A MULTICENTER GELTAMO/FIL STUDY

Authors Conclusion from the abstract: Our results indicate that ASCT in 1st CR improves the survival of patients with PTCL other than ALK+ anaplastic large‐cell lymphoma. These results should be confirmed in a prospective randomized study. A propensity score matching analysis is planned.

 

O. Tournilhac, Clermont-Ferrand (France), et al.

FIRST-LINE THERAPY OF T-CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION - FINAL RESULTS OF THE AATT STUDY

Authors Conclusion from the abstract:  AlloSCT or autoSCT given to consolidate response in pts with PTCL showed no significant survival differences. While exerting a strong GvL‐effect alloSCT resulted in substantial TRM. For younger pts with PTCL autoSCT remains the preferred consolidation, in particular, because pts relapsing after autoSCT can be successfully salvaged with alloSCT.
 

S. Qi, Beijing (China), et al.

TREATMENT BENEFIT ASSOCIATING WITH NON- ANTHRACYCLINE CHEMOTHERAPY IN EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE

Authors Conclusion from the abstract: Non‐ANT chemotherapy constituted the mainstay of chemotherapy in ENKL treatment. The application of non‐ANT chemotherapy associated improved response and survival comparing to ANT chemotherapy.

 

R. Tao, Shanghai (China), et al. 

SINTILIMAB FOR RELAPSED/REFRACTORY (R/R) EXTRANODAL NK/T CELL LYMPHOMA (ENKTL): A MULTICENTER, SINGLE-ARM, PHASE 2 TRIAL (ORIENT-4)

Authors Conclusion from the abstract: ORIENT‐4 is the first multicenter and prospective study validating efficacy of PD‐1 antibody in ENKTL and with results. Sintilimab is effective and well tolerated in r/r ENKTL and could be a promising treatment option for these patients. Early disease progression observed by PET scan in this study could be pseudo‐progression as it did not correlate with poor outcome, which warrants further investigation. Clinical trial information: NCT03228836